Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
AMES, Iowa, Aug. 29, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September:
- Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York City
- Cantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New York City
A live webcast of both conference presentations will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including PD-1 checkpoint blockade, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visit http://www.newlinkgenetics.com.
Investor Contact: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Media Contact: Andrew Mastrangelo AVP, Public & Media Relations LaVoieHealthScience 617-374-8800, ext. 108 [email protected]
